HIV Therapeutics Market Size to hit US$ 57.56 Billion by 2033: Global Data Report in 2025: Top 5 Companies are ViiV Healthcare ULC, Gilead Sciences, Inc., Pfizer Inc., Theratechnologies Inc., and Abbott Laboratories

global HIV therapeutics market size was US$ 37.61 Billion in 2024 and is expected to reach US$ 57.56 Billion by 2033, growing at a CAGR of 4.8% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/hiv-therapeutics-market?kb

Key Highlights From This Report

✅ North America leads the global HIV therapeutics market, holding the largest revenue share at 48.5% in 2024.

✅ The Asia Pacific region is the fastest-growing market, registering a CAGR of 7.7% in 2024.

✅ Nucleoside and nucleotide reverse transcriptase inhibitors remain the top drug class, accounting for 35.2% of the market in 2024.

✅ The oral route of administration dominates the market, capturing 70.3% of total share in 2024.

Key Players:

ViiV Healthcare ULC, Gilead Sciences, Inc., Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, AbbVie Inc., Boehringer Ingelheim International GmbH, Pfizer Inc., Theratechnologies Inc., and Abbott Laboratories,

Key industry Development:

✅ In July 2025, Merck reported that the U.S. FDA had accepted its New Drug Application for Doravirine/Islatravir (DOR/ISL), a once-daily oral two-drug regimen for adults with virologically suppressed HIV-1 who are already stable on antiretroviral therapy.

✅ In October 2025, ViiV Healthcare released 96-week findings from the PASO DOBLE (GeSIDA 11720) study, demonstrating that Dovato (dolutegravir/lamivudine) maintained virological suppression as effectively as Biktarvy, while resulting in significantly less weight gain and fewer treatment-related adverse events over two years.

✅ In July 2025, ViiV Healthcare expanded its voluntary licensing agreement with the Medicines Patent Pool (MPP) to include patents for its long-acting injectable regimen combining cabotegravir and rilpivirine, following updated WHO recommendations supporting this treatment as a global HIV therapy option.

✅ In July 2025, Gilead Sciences received FDA approval for a new indication of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), extending its use to treatment-experienced individuals with HIV who were not virologically suppressed and had no known or suspected resistance to INSTIs, emtricitabine, or tenofovir.

Growth Forecast Projection:

The Global HIV Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Latest Investments

US government and private sector collaborations invested over $26 million for research and implementation support under the Ending the HIV Epidemic (EHE) initiative, focusing on diverse populations and advancing prevention research.​

Japan's Shionogi reported a 5.7% increase in operating profit driven by strong royalties from its HIV franchise including Dovato and Apretude, signaling growth in commercial HIV therapeutics.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=hiv-therapeutics-market?kb

Key Segmentation:

By Drug Class: (Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, CCR5 Antagonists, Others)

By Route of Administration: (Oral, Parenteral)

By Distribution Channel; (Hospital Pharmacies, Retail Pharmacies),

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Latest M&A

Gilead Sciences acquired Interius BioTherapeutics, adding in vivo CAR-T cell therapy to its HIV pipeline in a $350 million deal driving next-gen HIV cure technologies.​

Multiple biotech acquisitions continue in the HIV space with companies like Concentra Biosciences acquiring late-stage HIV molecular candidates to diversify portfolios.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hiv-therapeutics-market?kb

Latest Drugs and Product Launches

✅ US FDA approved Gilead's Yeztugo® (lenacapavir), the first and only twice-yearly injectable HIV prevention drug for adults and adolescents, with efficacy demonstrated in Phase 3 trials showing near 100% prevention.​

✅ ViiV Healthcare's Cabenuva®, a once-monthly long-acting injectable HIV treatment, continues expanded usage with recent real-world data affirming high efficacy and adherence benefits.​

✅ Merck's doravirine (Pifeltro) single-agent treatment was recently approved, with ongoing studies supporting replacement of existing regimens for virologically suppressed patients.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/hiv-therapeutics-market?kb

Latest Clinical Trials

✅ Ongoing late-stage trials include lenacapavir combinations, long-acting PrEP evaluations, and cure research in both community-based and hospital settings.​

✅ Research initiatives in Japan focus on adapting combinations of antiretrovirals and long-acting injectables for local population efficacy and tolerability.​

Latest Project Hubs

✅ The USA hosts several NIH-funded research centers focusing on HIV prevention, treatment innovation, and cure trials, prominent hubs include Atlanta, San Francisco, and Boston.​

✅ In Japan, research collaborations between pharmaceutical companies, universities, and government agencies strengthen leading-edge HIV therapeutic development and clinical trial infrastructur

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.